BioSpace News Archive

Members of management of Surgery Partners, Inc., a leading short-stay surgical facility owner and operator, will be meeting with investors , January 10, 2022, as part of the 40th Annual J.P. Morgan Healthcare Conference, including a virtual presentation at 5:15 p.m. ET.

Singular Genomics Systems, Inc. announced a partnership with Dovetail Genomics to validate its proximity ligation kit portfolio, representing the leading methods to unlock access to 3-D genome architecture, with the G4 sequencing platform.

Singular Genomics Systems, Inc., a company leveraging novel next-generation sequencing and multiomics technologies to empower researchers and clinicians, announced a partnership with New England Biolabs to validate its NEBNext kits, a product line for both DNA and RNA sample prep, with the G4 sequencing platform.

Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the submission of a Fast Track Application to the U.S. Food and Drug Administration (FDA) for Tempol for the treatment and prevention of COVID-19.

InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced a new pipeline program, INF904, an oral small molecule inhibitor of C5aR.

COUR Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to the Company’s investigational therapy CNP-104 for the treatment of Primary Biliary Cholangitis.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced that Coherus has initiated the process to exercise its option to license JS006, Junshi Biosciences’ TIGIT-targeted antibody, in the United States and Canada, expanding the companies’ 2021 immuno-oncology collaboration agreement.

NEXGEL, Inc. today is providing shareholders with a 2021 year in review.

NervGen Pharma Corp. is pleased to announce it has entered into a Memorandum of Understanding with Shirley Ryan AbilityLab with the intention of performing NervGen’s first clinical trial with the Company’s proprietary NVG-291 in spinal cord injury (SCI) patients.

Company to present at 40th Annual J.P. Morgan Healthcare Conference today, January 10, 2022, at 2:15 - 2:55 p.m. ET / 7:15 - 7:55 p.m. GMT.